Literature DB >> 17499762

Indication for plasma exchange for systemic necrotizing vasculidities.

Loïc Guillevin1, Christian Pagnoux.   

Abstract

Plasma exchanges (PE) are a component of regimens prescribed to treat systemic necrotizing vasculidities. They are also part of the best therapeutic strategy for virus-induced vasculidities. The combination of antiviral agents and PE has proven efficacy against polyarteritis nordosa. This strategy is also effective for human immunodeficiency virus-associated vasculitis and, unlike cytotoxic agents, does not jeopardize the outcome of acquired immunodeficiency syndrome. Concerning the vasculitis seen in the context of hepatitis C virus-related cryoglobulinemia, PE contribute to better outcomes but, because of the poor efficacies of antiviral drugs, only about half of the patients achieve definitive recovery and relapses are frequent. The use of PE to treat antineutrophil cytoplasm antibody-associated vasculidities with severe renal insufficiency leads to improved renal function and thus fewer patients require dialysis. Although PE does not improve survival, their adjunction to corticosteroids and immunosuppressants for patients with alveolar hemorrhage could also limit the severity of this severe manifestation.

Entities:  

Mesh:

Year:  2007        PMID: 17499762     DOI: 10.1016/j.transci.2007.01.006

Source DB:  PubMed          Journal:  Transfus Apher Sci        ISSN: 1473-0502            Impact factor:   1.764


  3 in total

Review 1.  Biological Therapy-Induced Systemic Vasculitis.

Authors:  Luis Arturo Gutiérrez-González
Journal:  Curr Rheumatol Rep       Date:  2016-07       Impact factor: 4.592

2.  Vasculitic emergencies in the intensive care unit: a special focus on cryoglobulinemic vasculitis.

Authors:  Mohamad Zaidan; Eric Mariotte; Lionel Galicier; Bertrand Arnulf; Véronique Meignin; Jérôme Vérine; Alfred Mahr; Elie Azoulay
Journal:  Ann Intensive Care       Date:  2012-07-19       Impact factor: 6.925

3.  Life-Threatening Cryoglobulinemic Patients With Hepatitis C: Clinical Description and Outcome of 279 Patients.

Authors:  Soledad Retamozo; Cándido Díaz-Lagares; Xavier Bosch; Albert Bové; Pilar Brito-Zerón; Maria-Eugenia Gómez; Jordi Yagüe; Xavier Forns; Maria C Cid; Manuel Ramos-Casals
Journal:  Medicine (Baltimore)       Date:  2013-09       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.